Literature DB >> 6817570

Autoimmune haemolysis associated with Donath-Landsteiner antibodies.

R J Sokol, S Hewitt, B K Stamps.   

Abstract

The clinical pattern of haemolysis associated with Donath-Landsteiner antibodies has undergone a change over the years. In the current study 13 patients developed the acute form of the disease whilst only 1 presented with the classical picture of chronic paroxysmal cold haemoglobinuria. The acute illness typically occurred in young children with a male predominance of about 2.5:1; 10 patients were less than 5 years old. There was often a history of a preceding infection, the onset was sudden, prostration, haemoglobinuria and pallor were prominent. The patients were very ill but rapid and complete recovery usually occurred within a few days; however, 1 patient died. Treatment consisted of rest and warmth; in addition blood transfusion was needed in 7 patients. The chronic disease (which was non-syphilitic in origin) followed a benign course, warmth and avoidance of cold being all that were necessary to maintain the patient's well-being. It is felt that the general term for this disorder should be Donath-Landsteiner haemolysis rather than the traditional paroxysmal cold haemoglobinuria.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6817570     DOI: 10.1159/000206992

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  3 in total

Review 1.  Treatment of autoimmune hemolytic anemias.

Authors:  Alberto Zanella; Wilma Barcellini
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

2.  Acute renal failure in a patient with paroxysmal cold hemoglobinuria.

Authors:  Daljit K Hothi; Paul Bass; Mary Morgan; Jayshree Acharya; Steve E Humphries; Rodney D Gilbert
Journal:  Pediatr Nephrol       Date:  2006-11-23       Impact factor: 3.714

Review 3.  Autoimmune hemolytic anemia: From lab to bedside.

Authors:  R K Chaudhary; Sudipta Sekhar Das
Journal:  Asian J Transfus Sci       Date:  2014-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.